ObsEva SA (OBSV) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for OBSV in the last 30 days. The most recent was published Apr 26, 2023.

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.

Latest news

25 items

OBSV FAQ

8 questions
  • What does ObsEva SA do?
    ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age...
  • What is the latest news on OBSV?
    Quantisnow has not tracked any new filings, ratings or press releases for OBSV in the last 30 days. The most recent wire item was published on April 26, 2023.
  • Where does OBSV stock trade?
    ObsEva SA (OBSV) is listed on NASDAQ.
  • What sector and industry is OBSV in?
    ObsEva SA operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did ObsEva SA go public?
    ObsEva SA (OBSV) completed its IPO in 2017.
  • What are analysts saying about OBSV?
    Across the last 5 analyst actions on ObsEva SA, there were 0 upgrades and 1 downgrade. The most recent action was from H.C. Wainwright: Neutral on 2022-08-30. Recent price targets range from $6.00 to $15.00.
  • What companies are similar to OBSV?
    Notable peers in the same industry include MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson). Compare OBSV side-by-side with any of them on Quantisnow.
  • How can I track OBSV on Quantisnow?
    Quantisnow aggregates ObsEva SA's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OBSV to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change